首页> 外文期刊>Nature reviews neuroscience >Early cannulation grafts for haemodialysis: An updated systematic review
【24h】

Early cannulation grafts for haemodialysis: An updated systematic review

机译:用于血液透析的早期插管移植物:更新的系统审查

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: Early cannulation grafts are specifically designed for dialysis, whereas standard expanded polytetrafluoroethylene grafts were not. There is developing collective experience and literature available to allow the assessment of outcomes of these early cannulation grafts. The aim of this review was to review the evidence for both short- and long-term outcomes of early cannulation grafts. Methods: Using standardized searches of electronic databases in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses, the primary outcomes for this study were primary and secondary patency rates for early cannulation grafts for dialysis at 12 months and beyond. Secondary outcomes were timing of first cannulation, rates of access thrombosis, steal syndrome, pseudo-aneurysm and infection. Results: A total of 19 studies were identified and included. These were divided into different graft types. Flixene (TM), Avflo (TM), Acuseal (TM) and Vectra (TM) grafts all showed that early cannulation within 72 h is possible. Twelve-month pooled primary and secondary patency rates were 43.3% (95% confidence interval: 31.6-55.4) and 73.4% (95% confidence interval: 63-82.7) for the Flixene graft, 58.2% (95% confidence interval: 48-68.1) and 79.2% (95% confidence interval: 68-88.7) for the Avflo graft, 43.6% (95% confidence interval: 30.7-56.9) and 70.5% (95% confidence interval: 49.7-87.8) for the Acuseal graft and 63.7% (95% confidence interval: 53.4-73.4) and 85.8% (95% confidence interval: 82.9-88.4) for the Vectra graft. Data for outcome beyond 12 months were limited to the more recent studies. Conclusion: This review confirms that early cannulation is not detrimental on the early outcome of early cannulation graft patencies. It has also shown that both Vectra and Avflo grafts have adequate long-term patencies. The data do not allow specific graft recommendations, as comparative trials would be required.
机译:目的:早期的插管移植物专为透析设计,而标准的膨胀聚四氟乙烯移植物不是。有发展的集体经验和文学可用于允许评估这些早期插管移植物的结果。本综述的目的是审查早期插管移植物的短期和长期结果的证据。方法:根据首选报告项目,使用标准化的电子数据库搜索进行系统评价和荟萃分析,本研究的主要结果是在12个月及以后的透析透析的早期插管移植物的初级和二次通用速率。二次结果是第一次插管的时间,接入血栓形成的率,窃取综合征,假动脉瘤和感染。结果:鉴定并包括19项研究。这些被分成不同的接枝类型。氟烯(TM),AV​​FLO(TM),ACUSER(TM)和Vectra(TM)移植物都显示出72小时内的早期插管是可能的。汇集了12个月的汇集和二级通用率为43.3%(95%置信区间:31.6-55.4)和73.4%(31.6%(95%置信区间:63-82.7),58.2%(95%置信区间:48- 68.1)和79.2%(95%置信区间:68-88.7)为AVFLO移植物,43.6%(95%置信区间:30.7-56.9)和70.5%(95%置信区间:49.7-87.8),用于穴位接枝和63.7%(95%置信区间:53.4-73.4)和85.8%(95%置信区间:82.9-88.4),用于Vectra移植物。结果超过12个月的数据仅限于最近的研究。结论:本综述证实,早期插管对早期插管接枝等的早期结果并不有害。还表明Vectra和Avflo移植物都具有足够的长期级。数据不允许特定的移植建议,因为需要比较试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号